ALEVIATE: long term follow up study
Research type
Research Study
Full title
ALEmtuzumab for relapsing and refractory primary systemic VasculitIs – a Trial of Efficacy and safety (ALEVIATE): long term follow up study
IRAS ID
260928
Contact name
David Jayne
Contact email
Sponsor organisation
Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
Duration of Study in the UK
4 years, 0 months, 1 days
Research summary
Alemtuzumab is an effective drug for inducing remission (disease control) in primary systemic vasculitis (a rare group of conditions which cause inflammation of blood vessels) which has recurred after initial control (relapsed) or is particularly difficult to treat (refractory).
However, two longer term issues still need to be addressed :
1. This beneficial effect is not sustained long term and disease relapses frequently occur
2. At least 1 in 5 individuals go on to develop new onset autoimmunity (most commonly affecting the thyroid gland) after alemtuzumab
Alemtuzumab acts on lymphocytes (white blood cells) and by understanding how these cells recover in individual patients, we aim to identify patterns which may predict future clinical course.REC name
Wales REC 7
REC reference
19/WA/0254
Date of REC Opinion
2 Sep 2019
REC opinion
Favourable Opinion